US2018325980A1PendingUtilityA1

Composition for improving memory, learning ability, and cognitive ability

69
Assignee: BRAINON INCPriority: Dec 21, 2015Filed: Jun 17, 2018Published: Nov 15, 2018
Est. expiryDec 21, 2035(~9.4 yrs left)· nominal 20-yr term from priority
Inventors:Yong Koo Kang
A23L 33/18A61K 9/14A61P 25/28A61K 38/07C07K 5/1008C07K 5/1021C07K 5/0806C07K 5/06026A61K 9/0095A61K 9/0019
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided a composition for improving memory, learning ability, and cognitive ability. It has been confirmed that a peptide having a C-terminal region ended to GAG had an effect of improving the memory. In order for the peptide to have the effect, it has been confirmed that the peptide should be a peptide of which the length consists of at least 4 amino acids. Further, it has been confirmed that a peptide of which the length of the peptide having the C-terminal region ended to GAG consists of 5 to 9 amino acids has the same effect. As a result, the peptide of the present invention can be used as the composition for improving memory, learning ability, and cognitive ability.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A polynucleotide encoding the peptide comprising an amino acid sequence, wherein the amino acid sequence of the peptide is SEQ ID NO:3 (AGAG), SEQ ID NO:4 (QGAG), or SEQ ID NO:5 (GGAG). 
     
     
         2 . The polynucleotide of  claim 1 , wherein the polynucleotide is useful for preventing or treating a memory, cognitive, or learning disorder. 
     
     
         3 . The polynucleotide of  claim 1 , wherein the memory, cognitive, or learning disorder is a memory, cognitive, or learning disorder caused by aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, pick disease, Creutzfeldt-Jakob disease, depression, aging, head injury, stroke, CNS hypoxia, cerebral ischemia, encephalitis, forgetfulness, traumatic brain injury, hypoglycaemia, Wernicke-Korsakoff syndrome, drug addiction, epilepsy,  fasciola hepatica , hippocampal sclerosis, headache, brain aging, dementia, frontotemporal lobar degeneration, tumor, normal pressure hydrocephalus, HIV, cerebrovascular disease, cerebral disease, cardiovascular disease, amnesia, radiation exposure, metabolic disease, hypothyroidism, mild cognitive impairment, cognitive deficiency and attention deficit. 
     
     
         4 . A recombinant vector comprising the polynucleotide of  claim 1 . 
     
     
         5 . A method of preparing a peptide comprising incubating a host cell transformed with the recombinant vector of  claim 4 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.